1차 출처 기록
결정급탑라인 결과
Quince Therapeutics: LAM-001의 PH-ILD 2b상 데이터, 2028년 1분기 예상
Orphai Therapeutics 인수로 Quince의 파이프라인에 LAM-001이 추가되었습니다. PH-ILD 대상 75명 2b상 시험이 진행 중이며, 주요 결과는 2028년 1분기로 예정되어 있습니다. 별도의 BOS 2상 시험은 등록이 완료되었으며, 결과는 2027년 1분기로 예상됩니다.
핵심 사실
출처 발췌
EX-99.4 3 d163930dex994.htm EX-99.4 EX-99.4 Exhibit 99.4 BUSINESS Our Company We are a clinical-stage biopharmaceutical company developing a novel disease modifying therapeutic to address the significant unmet medical need associated with pulmonary disorders with few, if any, treatment options available. On May 18, 2026, we completed the acquisition of Orphai Therapeutics, a clinical-stage biopharmaceutical company developing therapies to treat serious, underserved pulmonary disorders. The acquisition brought into our pipeline Orphai’s lead asset, LAM-001, a proprietary investigational inhaled dry powder formulation of rapamycin whose differentiated characteristics may permit treatment of conditions associated with dysfunctional mammalian target of rapamycin (“mTOR”) activity that cann